Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

doi:10.3748/wjg.v17.i8.1082

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3808)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

331

HTML

3075

Figures (1-1)

213

Tables (1-1)

189

Sum=3808

Feb 28, 2011 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 28, 2011; 17(8): 1082-1087
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1082

Full Size Figure Download Figure

Figure 1 Overall survival curves for patients in PCF and FOLFOX-4 groups. PCF: Paclitaxel combined with fluorouracil plus cisplatin; FOLFOX-4: Oxaliplatin combined with fluorouracil plus leucovorin.

Citation: Li XD, Shen H, Jiang JT, Zhang HZ, Zheng X, Shu YQ, Wu CP. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol 2011; 17(8): 1082-1087
URL: https://www.wjgnet.com/1007-9327/full/v17/i8/1082.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i8.1082